Oculis Holding AG (ICE:OCS)
Iceland · Delayed Price · Currency is ISK | Market Cap | 85.12B -35.6% |
| Revenue (ttm) | 174.30M +49.9% |
| Net Income | -14.68B |
| EPS | -267.42 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 373 |
| Open | 1,415.00 |
| Previous Close | 1,400.00 |
| Day's Range | 1,415.00 - 1,420.00 |
| 52-Week Range | 1,290.00 - 4,180.00 |
| Beta | 0.20 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Oculis Holding AG
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company’s lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological da... [Read more]
Financial Performance
In 2025, Oculis Holding AG's revenue was 1.20 million, an increase of 74.78% compared to the previous year's 686,000. Losses were -98.96 million, 15.4% more than in 2024.
Financial numbers in CHF Financial StatementsNews
Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026
ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to ad...
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
ZUG, Switzerland, June 10, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.
Oculis Holding AG Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Following a setback in the DIAMOND trials, resources are now focused on advancing Privosegtor in neuro-ophthalmology and Licaminlimab in dry eye, both with innovative clinical strategies. Privosegtor targets large unmet needs and market potential, while a strong cash position supports ongoing development.
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
ZUG, Switzerland, June 9, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical ne...
Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference
Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing neuro-ophthalmic and ophthalmic diseases with significant u...
Oculis Holding AG Slides: Study update presentation
Oculis Holding AG has posted slides in relation to its latest quarterly earnings report, which was published on June 4, 2026.
Oculis price target lowered to $23 from $42 at JPMorgan
JPMorgan lowered the firm’s price target on Oculis (OCS) to $23 from $42 and keeps an Overweight rating on the shares. The firm cites the negative Phase 3 diabetic macular…
Oculis Holding AG Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Oculis Holding AG (NASDAQ: OCS) or certain of its executive officers violated federal securities laws. The in...
Oculis price target lowered to $38 from $49 at Baird
Baird lowered the firm’s price target on Oculis (OCS) to $38 from $49 and keeps an Outperform rating on the shares. The firm updated its model following news its OCS-01…
Oculis price target lowered to $38 from $49 at Baird
Baird lowered the firm’s price target on Oculis (OCS) to $38 from $49 and keeps an Outperform rating on the shares.
Oculis price target lowered to $35 from $44 at BofA
BofA lowered the firm’s price target on Oculis (OCS) to $35 from $44 and keeps a Buy rating on the shares. The firm removed OCS-01 in DME from its model…
Oculis price target lowered to $38 from $46 at Needham
Needham lowered the firm’s price target on Oculis (OCS) to $38 from $46 and keeps a Buy rating on the shares.
Oculis price target lowered to $45 from $75 at Guggenheim
Guggenheim lowered the firm’s price target on Oculis (OCS) to $45 from $75 and keeps a Buy rating on the shares after the company reported that the Phase 3 DIAMOND-1…
Oculis price target lowered to $26 from $47 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Oculis (OCS) to $26 from $47 and keeps a Buy rating on the shares. Results from the two Phase 3 DIAMOND trials…
Oculis price target lowered to $40 from $50 at Stifel
Stifel lowered the firm’s price target on Oculis (OCS) to $40 from $50 and keeps a Buy rating on the shares after the company halted further development for OCS-01 in…
Oculis Holding AG Transcript: Study result
Phase III trials of OCS-01 in DME failed to meet primary and key secondary endpoints, despite showing significant retinal thickness reduction and a favorable safety profile. No FDA filing will be pursued, and resources will shift to late-stage assets Privosegtor and licaminlimab.
Oculis Holding AG Press release: Study result
Oculis Holding AG issued a press release on May 29, 2026, disclosing material business information to investors.
Oculis Holding AG Slides: Study result
Oculis Holding AG has posted slides in relation to its latest quarterly earnings report, which was published on May 29, 2026.
Oculis Holding AG trading resumes
16:21 EDT Oculis (OCS) Holding AG trading resumes
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met The secondary endpoint of retinal thickness showed a substantial...
Oculis reports primary endpoint of DIAMOND Phase 3 trials was not met
Oculis (OCS) Holding announced topline results from its Phase 3 DIAMOND-1 and DIAMOND-2 trials of OCS-01 eye drops in patients with diabetic macular edema. The DIAMOND program consisted of two…
Oculis Holding AG trading halted, news pending
14:43 EDT Oculis (OCS) Holding AG trading halted, news pending
Oculis quickly falls 26% to $22 per share
Oculis (OCS) shares have plunged $7.65, or 26% to $22.00 in afternoon trading.
Oculis initiated with a Buy at Guggenheim
Guggenheim initiated coverage of Oculis (OCS) with a Buy rating and $75 price target The firm sees OCS-01 having the potential to become the first non-invasive topical treatment for DME,…
Oculis price target raised to $42 from $38 at JPMorgan
JPMorgan raised the firm’s price target on Oculis (OCS) to $42 from $38 and keeps an Overweight rating on the shares. The firm expects topline results in a joint disclosure…